Sublingual Immunotherapy for Allergic Rhinitis

Cox, Linda

doi:10.1001/jama.2017.0128

Cited by 14 publications

(8 citation statements)

References 17 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subcutaneous and sublingual immunotherapies for respiratory allergy are highly effective and represent the most widely prescribed routes of administration [ 7 , 12 – 15 ]. An essential question is whether allergen immunotherapy provides a sustained clinical effect after treatment cessation.…”

Section: Discussionmentioning

confidence: 99%

“…An essential question is whether allergen immunotherapy provides a sustained clinical effect after treatment cessation. Lack of this prolonged effect would question the viability of immunotherapy as an alternative to standard pharmacotherapy due to cost, potential side effects and the time commitment and inconvenience involved for patients [ 15 , 19 , 36 ].…”

Section: Discussionmentioning

confidence: 99%

“…Allergen immunotherapy administered subcutaneously (SCIT) has been the standard practice to treat AR whereas the sublingual route (SLIT) has emerged as an effective and safe alternative [ 7 , 13 – 15 ]. Subcutaneous immunotherapy comprises the repeated administration of increasing concentrations of the relevant allergen weekly for 3–5 months followed by monthly maintenance injections [ 7 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis

Penagos

Eifan

Durham

et al. 2018

Curr Treat Options Allergy

View full text Add to dashboard Cite

RationaleSubcutaneous and sublingual immunotherapy are effective for allergic rhinitis. An important question is whether allergen immunotherapy provides a sustained clinical effect after treatment cessation. In view of potential side effects, cost and the necessary patient commitment, long-term benefit is an important consideration for the recommendation of immunotherapy over standard pharmacotherapy.Purpose of reviewIn this review, we analyse the existing evidence for long-term effects of both routes of administration in the context of double-blind, placebo-controlled, randomised clinical trials that included a follow-up phase of at least 1 year after treatment cessation.Recent findingsOverall, evidence suggests that 3 years of either subcutaneous or sublingual immunotherapy result in clinical benefit and immunological changes consistent with allergen-specific tolerance sustained for at least 2–3 years after treatment cessation.SummaryThe data presented here support recommendations in international guidelines that both routes of administration should be continued for a minimum of 3 years. Gaps in the evidence remain regarding the long-term efficacy of immunotherapy for perennial rhinitis and studies performed in children.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis

Penagos

Eifan

Durham

et al. 2018

Curr Treat Options Allergy

View full text Add to dashboard Cite

show abstract

“…66 Several long-term studies have shown that the effectiveness of AIT and its potential for preventing the onset of allergic asthma and new sensitizations is dependent on its duration of use, with successful outcomes (ie, disease modification) achieved only after completion of the recommended 3-year treatment course. [67][68][69] However, RWE from NRS using pharmaceutical prescription databases suggests that AIT treatment effect persistence (ie, the completion of the 3-yearcourse) is achieved by <40% of patients receiving SCIT, and <10% of patients usingSLIT. [70][71][72] A frequent issue in these trial is patient attrition.…”

Section: Appr Ais Ing the Qualit Y Of Rwe In Aitmentioning

confidence: 99%

Allergen immunotherapy: The growing role of observational and randomized trial “Real‐World Evidence”

Paoletti

Bona

Chu

et al. 2021

Allergy

View full text Add to dashboard Cite

Background: Although there is a considerable body of knowledge about allergen immunotherapy (AIT), there is a lack of data on the reliability of real-world evidence (RWE) in AIT, and consequently, a lack of information on how AIT effectively works in real life. Methods:To address the current unmet need for an appraisal of the quality of RWE in AIT, the European Academy of Allergy and Clinical Immunology Methodology Committee recently initiated a systematic review of observational studies of AIT, which will use the RELEVANT tool and the Grading of Recommendations Assessment, Development and Evaluation approach (GRADE) to rate the quality of the evidence base as a whole. The next step will be to develop a broadly applicable, pragmatic "real-world" database using systematic data collection. Based on the current RWE base, and perspectives and recommendations of authorities and scientific societies, aGlobally, SLIT appears to be the most common route of administration of AIT, as demonstrated by an analysis of the worldwide market hierarchy of RWE in AIT is proposed, which places pragmatic trials and registry data at the positions of highest level of evidence. Key Results:There is a need to establish more AIT registries that collect data in a cohesive way, using standardized protocols.Conclusions: This will provide an essential source of real-world data that can be easily shared, promoting evidence-based research and quality improvement in study design and clinical decision-making.

show abstract

“…АР -заболевание, характеризующееся наличием иммунологически обусловленного (чаще всего IgEзависимого) воспаления слизистой оболочки носа, вызванного причинно-значимым аллергеном, и клинически проявляющееся двумя и более симптомами: обильной ринореей, затруднением носового дыхания, зудом в полости носа, повторяющимся чиханьем и нередко аносмией [4].…”

Section: аллергический ринитunclassified

Possibilities of azelastine in the treatment of chronic rhinitis

Смирнов

Курбачева

2017

Vestn. otorinolaringol.

View full text Add to dashboard Cite

show abstract

Sublingual Immunotherapy for Allergic Rhinitis

Abstract: Genetic association of waist-to-hip ratio with cardiometabolic traits, type 2 diabetes, and coronary heart disease. JAMA.

Cited by 14 publications

References 17 publications

Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis

Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis

Allergen immunotherapy: The growing role of observational and randomized trial “Real‐World Evidence”

Possibilities of azelastine in the treatment of chronic rhinitis

Contact Info

Product

Resources

About